Pulmonary arterial hypertension (PAH) is a progressive condition where small lung arteries become abnormally thick and narrow, increasing blood flow resistance and forcing the heart’s right ventricle to work harder and eventually fail. While PAH remains a life-shortening condition, the past four decades have yielded notable progress in understanding its pathobiology, improving diagnostic precision, and expanding therapeutic options that extend survival. Yet this progress coincides with a shifting patient landscape: PAH now more commonly affects older adults managing additional cardiovascular and pulmonary comorbidities.
To synthesize these milestone advances and outline future priorities, CVC faculty member Dr. Jason Weatherald and colleagues analyzed 40 years of PAH research in a recent Circulation state-of-the-art review.
A primary goal in PAH care is closing the diagnostic gap, as patients often face long delays before receiving targeted therapy. While right heart catheterization remains the gold standard for confirmation, emerging artificial intelligence tools applied to ECGs, imaging, and electronic health records show promise for earlier detection. Once diagnosed, doctors use standardized, multi-factor risk scores to regularly reassess prognosis and guide whether treatment should be escalated or scaled back.
Therapeutic strategies have transformed from basic symptom management to actively altering disease progression. Most patients now start on combination therapy using two oral drugs that relax pulmonary vessels through different pathways, while high-risk patients may begin with a more intensive three-drug regimen that adds a non-oral prostacyclin, given intravenously or subcutaneously. More recently, targeting the TGF-β pathway to reverse structural vessel changes led to the approval of sotatercept, the first anti-remodeling therapy for PAH. In clinical trials, adding sotatercept for intermediate or high-risk patients improved cardiac hemodynamics and significantly reduced the risk of death or disease progression, though it carries notable risks, including bleeding events and blood count changes requiring monitoring.
Ultimately, four decades of research have fundamentally reshaped PAH care, meaningfully improving patient outcomes and expanding therapeutic avenues. Nevertheless, diagnostic delays and progressive right heart failure remain persistent hurdles. To build on this momentum, the authors emphasize that future research must focus on establishing screening methods for earlier case identification, tailoring therapies for complex older patients, and developing treatments that directly target and protect the failing right heart.
